.jpg)
Kymera reports Phase 1 data for pill to rival Dupixent
The small biotech Kymera Therapeutics believes it could have a potential oral competitor to the megablockbuster Dupixent. There’s a long road ahead for Kymera’s immunology drug candidate, a protein degrader targeting STAT6 called KT-621. But ...
The small biotech Kymera Therapeutics believes it could have a potential oral competitor to the megablockbuster Dupixent.
There’s a long road ahead for Kymera’s immunology drug candidate, a protein degrader targeting STAT6 called KT-621. But ...
